- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07484139
H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) och Pembrolizumab (Keytruda) i kirurgiskt resektabel, HPV-negativ skivepitelcancer i munhålan (OCSCC) (NEO COMBAT XL)
H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) och Pembrolizumab (Keytruda) vid kirurgiskt resektabel, HPV-negativ skivepitelcancer i munhålan (OCSCC)
This is a multicenter, single arm Phase 2B study in subjects with locally advanced oral cavity squamous cell carcinoma (OCSCC) with surgically resectable disease. The study will assess the combination of neoadjuvant XL092 and pembrolizumab for safety and improvement of pathologic response rates compared to historical standard of care with perioperative pembrolizumab. The primary objective is to estimate the pathologic response rate defined as either pathological complete response (pCR), which is the absence of residual viable tumor, or major pathologic response (MPR), which is <10% of residual tumor following the completion of neoadjuvant therapy and surgery. The study will be conducted in two stages. Per Simon's Stage 1, 11 patients will be enrolled. Simon Stage 2 will be gated on multiple factors. If ≥2 pathologic response is observed (pCR or MPR), the trial will proceed with cohort expansion and enroll an additional 15 patients for a total of 26 patients.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
Kontakter och platser
Studiekontakt
- Namn: Rose Hall
- Telefonnummer: 919-984-0000
- E-post: rose_hall@med.unc.edu
Studera Kontakt Backup
- Namn: Shamina Williams
- Telefonnummer: 919-984-0000
- E-post: shamina_williams@med.unc.edu
Studieorter
-
-
Georgia
-
Atlanta, Georgia, Förenta staterna, 30322
- Har inte rekryterat ännu
- Emory University
-
Kontakt:
- Nikki C Schmitt
- E-post: Nicole.cherie.schmitt@emory.edu
-
Huvudutredare:
- Nikki C Schmitt, MD
-
-
North Carolina
-
Chapel Hill, North Carolina, Förenta staterna, 27599
- Rekrytering
- University of North Carolina at Chapel Hill
-
Kontakt:
- Siddharth Sheth, MD
- E-post: siddharth.sheth@unchealth.unc.edu
-
Kontakt:
- Rose Hall, MSW
- Telefonnummer: 984-974-8440
- E-post: rose_hall@med.unc.edu
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Förenta staterna, 19107
- Har inte rekryterat ännu
- Thomas Jefferson University
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information.
- Subject is willing and able to comply with study procedures based on the judgement of the investigator or protocol designee.
- Age ≥ 18 years at the time of consent.
- Tumors must have PD-L1 Combined Positive Score (CPS) ≥ 1.
- ECOG or Karnofsky Performance Status of 0-1
- Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) within 30 days prior to treatment .
Exclusion Criteria:
- Known HPV-positive cancer
- Active infection requiring systemic therapy.
- Prior treatment with XL-092
- Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study).
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Locally advanced oral cavity squamous cell carcinoma
Locally advanced oral cavity squamous cell carcinoma (OCSCC) with surgically resectable disease. |
60 mg oral once a day 200 mg intravenous for 30 minutes in every 21 days for |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Rate of pathologic response
Tidsram: Up to 66 days
|
Rate of pathologic response, assessed following surgery, will be defined as either pathological complete response (pCR), which is the absence of residual viable tumor or major pathological response (MPR), which is <10% residual tumor. |
Up to 66 days
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Neoadjuvant Adverse Events
Tidsram: Up to 66 days
|
Safety will be defined as the rate of treatment emergent adverse events with neoadjuvant XL-092 and pembrolizumab (CTCAE v5.0). |
Up to 66 days
|
|
Events Free Survival (EFS)
Tidsram: Up to 15 months
|
EFS will be defined as the time from first treatment to an event which may include disease progression, discontinuation of the treatment for any reason, or death from any cause, where disease progression will be determined based on Radiographic response will be measured according to Response Evaluation Criteria In Solid Tumors Criteria 1.1 (RECIST 1.1). RECIST indicating if subject experienced a Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), no response or less response than Partial or Progressive; or Progressive Disease (PD), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. |
Up to 15 months
|
|
Objective response rate (ORR)
Tidsram: Up to 15 months
|
ORR following neoadjuvant therapy: an objective response will be classified per the Radiographic response will be measured according to Response Evaluation Criteria In Solid Tumors Criteria 1.1 (RECIST 1.1) if a partial or complete response is observed. RECIST indicating if subject experienced a Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), no response or less response than Partial or Progressive; or Progressive Disease (PD), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. |
Up to 15 months
|
|
Time to surgery
Tidsram: Up to 66 days
|
Time to surgery: defined as the time from completion of neoadjuvant therapy to date of surgery. Individuals who do not receive surgery due to progressive disease, non-TEAE death or individuals who experience surgery delays due to toxicity will not be counted. |
Up to 66 days
|
|
Overall survival (OS)
Tidsram: Up to 15 months
|
OS is defined as the time from time of first treatment to death due to any cause. |
Up to 15 months
|
Samarbetspartners och utredare
Samarbetspartners
Utredare
- Huvudutredare: Siddharth Sheth, MD, UNC Lineberger Comprehensive Cancer Center
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- LCCC2517
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .